Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical isn’t your ordinary biotech company.

It’s out to help those who are suffering from cancer, diabetes, respiratory infections, heart disease, and arthritis — all by focusing on one particular problem.

That problem is inflammation. Perhaps surprisingly, eighty percent of all major human diseases are a result of inflammation. And 150 million Americans suffer from it.

By repurposing FDA-approved small molecules, Sen-Jam is developing innovative, proprietary, potent anti-inflammatory medicines. As the company says, its approach to treating inflammation is the biggest pharmacological advancement since aspirin was invented 125 years ago.

Sen-Jam is led by scientific advisors with experience at the Mayo Clinic, Boston Medical Clinic, Harvard School of Public Health, and Cornell University.

Team Background

Jim Iversen - Co-Founder & CEO

Jim is a serial entrepreneur who’s completed five previous successful exits.

Prior to Sen-Jam, he was CEO of JMI Capital Group, a consulting business focused on leadership. Before that, he was an advisor and board member with W&H Systems, a logistics and supply-chain company, where he served as CEO earlier in his career.

For three years, he was CEO of Horizon Foods, a food-products company, and before that spent ten years as CEO of AL Systems, a software-development company.

Jim earned a Bachelor’s degree in Mechanical Engineering and Computer Science from New Jersey Institute of Technology.

Jackie Iversen - Co-Founder & Head of Clinical Development

Jackie is a pharmacist and clinical-research expert in pharmacokinetics and pain management.

Prior to Sen-Jam, she was a hospital pharmacist at Northwell Health, New York state’s largest health-care provider. Before that, she completed a pharmacy-research fellowship at Memorial Sloan Kettering Cancer Center. Throughout her career, her work has been cited in more than twenty scientific publications.

She holds a Bachelor’s degree in Pharmacy from the University of Buffalo and a Master’s degree in Clinical Pharmacy from St. John’s University.

Thomas Dahl - Head of Product Development

Tom is a pharmaceutical clinical development and regulatory expert.

He has held several senior-management positions with companies ranging from startups to established global operations. His expertise includes technical analysis of products and technologies, business strategy and operations, development-program strategy, clinical-trial design, and interfacing with pharmaceutical partners.

He holds a Ph.D. in Biochemistry and Biology from Johns Hopkins University.

Co-Investors